VIVEbiotech drives in vivo gene therapy forward with GMP lentiviral vectors
Currently supporting 10 in-vivo lentiviral vector programs, two of which are already in clinical trials.
In vivo gene therapy is moving fast — and the lentiviral vectors powering it are being manufactured by VIVEbiotech.
We are currently supporting 10 client programs that use in-vivo lentiviral vectors, with 2 already in clinical trials.
These therapies span multiple areas, including:
- CAR-Ts
- Vaccines
- Virus-like particles (VLPs)
- Rare disease treatments, with both systemic and local delivery
As a GMP CDMO with a Manufacturer’s Authorisation for lentiviral vectors as final product, VIVEbiotech is fully licensed to supply vectors for in vivo use — positioning us as a trusted partner in the development of advanced gene therapies.
Are you developing an in vivo lentiviral program? Reach out.
The in vivo era has begun — and we are proud to support our partners as they lead it.
Jon Alberdi, CEO of VIVEbiotech, tells it here: https://www.youtube.com/watch?v=tN3XO40nIYY